News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
37,944 Results
Type
Article (2421)
Company Profile (39)
Press Release (35484)
Section
Business (14114)
Career Advice (77)
Deals (2075)
Drug Delivery (8)
Drug Development (4093)
Employer Resources (10)
FDA (429)
Job Trends (761)
News (20123)
Policy (1051)
Tag
2024 BioForest Digital (4)
2024 BioMidwest Digital (2)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Digital (1)
2024 Biotech Beach Standard (1)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (1)
2025 Lone Star Bio Digital (1)
Academia (143)
Allergies (4)
Alliances (3465)
ALS (4)
Alzheimer's disease (44)
Antibody-drug conjugate (ADC) (14)
Approvals (431)
Artificial intelligence (8)
Autoimmune disease (2)
Automation (1)
Bankruptcy (11)
Best Places to Work (475)
BIOSECURE Act (2)
Biosimilars (10)
Biotechnology (29)
Bladder cancer (5)
Brain cancer (5)
Breast cancer (16)
Cancer (112)
Cardiovascular disease (4)
Career advice (64)
Career pathing (1)
CAR-T (14)
Cell therapy (41)
Cervical cancer (2)
Clinical research (3157)
Collaboration (83)
Compensation (41)
COVID-19 (180)
CRISPR (7)
C-suite (22)
Cystic fibrosis (2)
Data (91)
Denatured (3)
Depression (3)
Diabetes (9)
Diagnostics (461)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (13)
Drug pricing (7)
Duchenne muscular dystrophy (10)
Earnings (4196)
Editorial (2)
Employer branding (1)
Employer resources (8)
Events (5971)
Executive appointments (82)
FDA (468)
Featured Employer (3)
Funding (70)
Gene editing (14)
Gene therapy (14)
GLP-1 (59)
Government (149)
Healthcare (702)
Huntington's disease (3)
IgA nephropathy (3)
Immunology and inflammation (12)
Indications (2)
Infectious disease (185)
Inflammatory bowel disease (11)
Inflation Reduction Act (6)
Influenza (4)
Intellectual property (10)
Interviews (7)
IPO (985)
IRA (7)
Job creations (290)
Job search strategy (62)
Kidney cancer (4)
Labor market (3)
Layoffs (36)
Leadership (1)
Legal (212)
Liver cancer (5)
Lung cancer (15)
Lymphoma (3)
Management (4)
Manufacturing (17)
MASH (3)
Medical device (306)
Medtech (306)
Mergers & acquisitions (1146)
Metabolic disorders (30)
Multiple sclerosis (6)
Neurodegenerative disease (7)
Neuropsychiatric disorders (3)
Neuroscience (85)
NextGen: Class of 2025 (352)
Non-profit (153)
Northern California (313)
Now hiring (4)
Obesity (15)
Opinion (15)
Ovarian cancer (9)
Pain (7)
Pancreatic cancer (3)
Parkinson's disease (4)
Partnered (1)
Patents (18)
Patient recruitment (2)
Peanut (1)
People (5616)
Pharmaceutical (5)
Phase I (1362)
Phase II (1583)
Phase III (843)
Pipeline (52)
Podcasts (4)
Policy (10)
Postmarket research (30)
Preclinical (584)
Press Release (2)
Prostate cancer (3)
Psychedelics (2)
Radiopharmaceuticals (12)
Rare diseases (19)
Real estate (419)
Recruiting (5)
Regulatory (794)
Reports (6)
Research institute (142)
Resumes & cover letters (9)
Schizophrenia (10)
Series A (21)
Series B (4)
Service/supplier (2)
Sickle cell disease (1)
Southern California (315)
Special edition (1)
Sponsored (1)
Startups (487)
Stomach cancer (1)
Supply chain (4)
The Weekly (1)
United States (1523)
Vaccines (26)
Venture capitalists (7)
Webinars (2)
Weight loss (10)
Women's health (1)
Worklife (1)
Date
Today (15)
Last 7 days (47)
Last 30 days (240)
Last 365 days (2557)
2025 (491)
2024 (2611)
2023 (2858)
2022 (3755)
2021 (4052)
2020 (3471)
2019 (2061)
2018 (1554)
2017 (1798)
2016 (1625)
2015 (1833)
2014 (1369)
2013 (1188)
2012 (1396)
2011 (1332)
2010 (1181)
Location
Africa (43)
Alabama (1)
Arizona (14)
Asia (1851)
Australia (297)
California (724)
Canada (124)
China (34)
Colorado (18)
Connecticut (10)
Delaware (3)
Europe (3802)
Florida (43)
Georgia (4)
Idaho (3)
Illinois (14)
India (1)
Indiana (28)
Japan (7)
Kansas (12)
Maryland (24)
Massachusetts (264)
Michigan (8)
Minnesota (14)
Missouri (3)
Nebraska (1)
Nevada (2)
New Hampshire (1)
New Jersey (59)
New York (43)
North Carolina (82)
Northern California (313)
Ohio (25)
Oklahoma (2)
Oregon (4)
Pennsylvania (36)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (315)
Tennessee (2)
Texas (62)
Utah (2)
Virginia (5)
Washington D.C. (1)
Washington State (40)
Wisconsin (6)
37,944 Results for "caladrius biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius”) and Cend Therapeutics, Inc. (“Cend”) today announced that the proposed merger of the two companies has closed following the approval of Caladrius’ stockholders on September 13, 2022.
September 15, 2022
·
8 min read
Layoffs
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
Staff cuts will leave IGM Biosciences with 37 employees. The company is also halting development of two bispecific antibody T cell engagers for autoimmune diseases.
January 10, 2025
·
1 min read
·
Angela Gabriel
Pharm Country
Caladrius Biosciences to Present at the BIO International Convention 2022
Caladrius Biosciences, Inc. announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the BIO International Convention being held in-person at the San Diego Convention Center in San Diego, CA, from June 13-16, 2022.
June 8, 2022
·
1 min read
Pharm Country
Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics
Caladrius Biosciences, Inc., announced that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of stockholders held September 13, 2022, its stockholders approved all of the merger-related proposals.
September 14, 2022
·
6 min read
Deals
Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of Caladrius in an all-stock approximate “merger of equals” transaction unanimously approved by the Boards of Directors of each company.
April 27, 2022
·
13 min read
Drug Development
Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in The Lancet Gastroenterology and Hepatology
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), and Cend Therapeutics, Inc. (“Cend”), today announced that The Lancet Gastroenterology and Hepatology has published data from the Phase 1b study of CEND-1.
July 6, 2022
·
11 min read
Press Releases
Aura Biosciences to Participate in Upcoming Investor Conferences
February 26, 2025
·
1 min read
Pharm Country
Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference
Caladrius Biosciences, Inc. announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius, will present a corporate overview at the H.C. Wainwright Global Investment Conference being held both virtually and in-person at the Fontainebleau Miami Beach Hotel in Miami, FL on May 23-26, 2022.
May 18, 2022
·
2 min read
Pharm Country
Caladrius Biosciences to Present at the BIO CEO & Investor Conference
Caladrius Biosciences, Inc. announced that David J. Mazzo, PhD, President and CEO of Caladrius, will be presenting a corporate overview at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis in NYC on February 14-15 and virtually through the 17th.
February 8, 2022
·
1 min read
Business
Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, reported financial results for the three and six months ended June 30, 2022 and provided a business update.
August 4, 2022
·
16 min read
1 of 3,795
Next